Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Ribociclib,Anastrozole
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Kisqali® (ribociclib) is the only USFDA approved category 1 preferred CDK4/6 inhibitor for first-line treatment of patients with HR+/HER2- MBC when combined with an AI.
Product Name : Kisqali
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 27, 2023
Lead Product(s) : Ribociclib,Anastrozole
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Giredestrant,Palbociclib
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : F. Hoffmann-La Roche
Deal Size : Inapplicable
Deal Type : Inapplicable
TRIO Enrols First Patient in Global Phase 3 Giredestrant Early Breast Cancer Trial
Details : Giredestrant is an oral selective estrogen receptor degrader (SERD) that was shown to be well tolerated with encouraging anti-tumour activity both alone and in combination with palbociclib in estrogen-receptor positive (ER+) metastatic breast cancer pati...
Product Name : GDC-9545
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 31, 2021
Lead Product(s) : Giredestrant,Palbociclib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : F. Hoffmann-La Roche
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Giredestrant,Palbociclib
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : F. Hoffmann-La Roche
Deal Size : Inapplicable
Deal Type : Inapplicable
TRIO Completes Enrolment for Phase 2 Giredestrant Early Breast Cancer Trial Ahead of Schedule
Details : Giredestrant is an oral selective estrogen receptor degrader (SERD) that was shown to be well tolerated with encouraging tumour activity both alone and in combination with palbociclib in estrogen-receptor positive (ER+) metastatic breast cancer patients.
Product Name : GDC-9545
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 07, 2021
Lead Product(s) : Giredestrant,Palbociclib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : F. Hoffmann-La Roche
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ribociclib,Fulvestrant
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
TRIO Completes Enrollment of Phase III NATALEE Breast Cancer Clinical Trial
Details : Ribociclib belongs to a class of targeted therapies called CDK4/6 inhibitors. Cyclin-dependent kinases 4 and 6 are proteins that help regulate cell replication and proper cell cycle function.
Product Name : Kisqali
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 21, 2021
Lead Product(s) : Ribociclib,Fulvestrant
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
